Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial

SOPHIA Study Group

Research output: Contribution to journalArticleAcademicpeer-review

35 Citations (Web of Science)
Original languageEnglish
Pages (from-to)573-584
Number of pages12
JournalJAMA Oncology
Volume7
Issue number4
Early online date22 Jan 2021
DOIs
Publication statusPublished - Apr 2021

Keywords

  • association
  • benefit
  • c receptor polymorphisms
  • chemotherapy
  • immunity
  • monoclonal-antibody
  • recommendations
  • survival
  • therapy
  • SURVIVAL
  • IMMUNITY
  • MONOCLONAL-ANTIBODY
  • CHEMOTHERAPY
  • C RECEPTOR POLYMORPHISMS
  • BENEFIT
  • THERAPY
  • RECOMMENDATIONS
  • ASSOCIATION

Cite this